The role of aminogenic glucagon secretion in blood glucose homeostasis.

Hyperaminoacidemia is a powerful stimulus of pancreatic glucagon secretion. These studies were designed to elucidate the role of aminogenic hyperglucagonemia in glucoregulation. Conscious dogs with previously implanted indwelling venous catheters were employed. The results support the view that a role of glucagon is to limit blood glucose decline during hyperaminoacidemia.First, a significant negative correlation between the area of glucagon increment during the 1st 20 min of a 10 amino acid infusion and the maximum fall in glucose concentration was observed. Second, when endogenous glucagon secretion was suppressed by means of a continuous glucose infusion, hyperaminoacidemia induced a maximal glucose decline which averaged 35 mg/100 ml, differing significantly from mean maximal fall of 3 mg/100 ml, which normally occurs in the presence of endogenous hyperglucagonemia. Third, when, during hyperglycemic suppression of endogenous glucagon secretion, 50 mmug of exogenous glucagon/min was infused via the mesenteric vein with the amino acids, the fall in glucose was reduced to an average of 5 mg/100 ml. Similarly when pancreozymin, administered during the combined infusion of glucose and amino acids, overcame glucose suppression of endogenous glucagon secretion, plasma glucose did not fall. Similar results were obtained when aminogenic hyperglucagonemia was prevented by other means. Hyperlipacidemia, induced by infusing a triglyceride emulsion and giving heparin injections, also suppressed aminogenic hyperglucagonemia in two of four experiments; in these two dogs glucose fell 15 and 11 mg/100 ml. In a final group of experiments, the canine pancreas was resected except for the uncinate process, which is virtually devoid of alpha-cells. In two dogs, in which this procedure resulted in zero portal venous glucagon levels, the administration of amino acids and/or pancreozymin resulted in a glucose decline of 14 and 16 mg/100 ml, despite the reduced beta-cell population resulting from the subtotal pancreotectomy. It thus appears that the secretion of pancreatic glucagon during hyperaminoacidemia in association with insulin secretion, serves to limit the decline of glucose concentration.

[1]  R. Unger,et al.  Control of Pancreatic Glucagon Secretion by Glucose , 1969, Diabetes.

[2]  R. Unger,et al.  Characterization of response of circulating glucagon to intraduodenal and intravenous administration of amino acids. , 1968, The Journal of clinical investigation.

[3]  H. Burger,et al.  Non-specificity of arginine infusion as a test for growth-hormone secretion. , 1968, Lancet.

[4]  R. Unger,et al.  Effect on plasma free fatty acids on plasma glucagon and serum insulin concentrations. , 1968, Metabolism: clinical and experimental.

[5]  R. Unger,et al.  The effects of secretin, pancreozymin, and gastrin on insulin and glucagon secretion in anesthetized dogs. , 1967, The Journal of clinical investigation.

[6]  J. Barboriak,et al.  Stimulation of Insulin Secretion by Pancreozymin , 1967, Diabetes.

[7]  R. Assan,et al.  [The effects of perfusion and amino acid ingestion in glucagonenemia]. , 1967, Journees annuelles de diabetologie de l'Hotel-Dieu.

[8]  S. Fajans,et al.  Effect of amino acids and proteins on insulin secretion in man. , 1967, Recent progress in hormone research.

[9]  T. Merimee,et al.  Growth hormone and insulin release after arginine: indifference to hyperglycemia and epinephrine. , 1966, The Journal of clinical endocrinology and metabolism.

[10]  S. Fajans,et al.  Insulin secretion in response to protein ingestion. , 1966, The Journal of clinical investigation.

[11]  T. Merimee,et al.  Effect of arginine on serum-levels of human growth-hormone. , 1965, Lancet.

[12]  S. Fajans,et al.  PLASMA GROWTH HORMONE RESPONSE TO INTRAVENOUS ADMINISTRATION OF AMINO ACIDS. , 1965, The Journal of clinical endocrinology and metabolism.

[13]  F. Mosinger PHOTOMETRIC ADAPTATION OF DOLE'S MICRODETERMINATION OF FREE FATTY ACIDS. , 1965, Journal of lipid research.

[14]  R. Unger,et al.  THE EFFECTS OF COCL-2 ON GLUCAGON LEVELS IN PLASMA AND PANCREAS OF THE RAT. , 1964, Metabolism: clinical and experimental.

[15]  E. Newsholme,et al.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. , 1963, Lancet.

[16]  R. Unger,et al.  Measurements of endogenous glucagon in plasma and the influence of blood glucose concentration upon its secretion. , 1962, The Journal of clinical investigation.

[17]  S. Berson,et al.  Immunoassay of Endogenous Plasma Insulin in Man , 1960 .

[18]  I. Wool,et al.  Incorporation of C14-histidine into protein of isolated diaphragms: interaction of fasting, glucose and insulin. , 1959, The American journal of physiology.

[19]  S A BENCOSME,et al.  Regional differences of the pancreatic islet. , 1955, Endocrinology.

[20]  A. Kenny Extractable glucagon of the human pancreas. , 1955, The Journal of clinical endocrinology and metabolism.

[21]  E. Frame,et al.  The colorimetric estimation of amino nitrogen in blood. , 1943 .

[22]  W. Hoffman A RAPID PHOTOELECTRIC METHOD FOR THE DETERMINATION OF GLUCOSE IN BLOOD AND URINE , 1937 .